ALKS (Alkermes) E10: $-0.19 (As of Mar. 2026)


ALKS Alkermes PLC ALKS
70 GF Score
Price $53.14
GF Value $31.33
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Alkermes E10?

Alkermes ALKS +5.33% 70 E10 is $-0.19 as of Mar. 2026. GuruFocus rates ALKS with a GF Score™ of 70/100 and a GF Value™ of $31.33 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Alkermes's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.400. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.19 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 38.90% per year. During the past 5 years, the average E10 Growth Rate was 20.50% per year. During the past 10 years, the average E10 Growth Rate was -18.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Alkermes was 60.70% per year. The lowest was -225.50% per year. And the median was 0.80% per year.

As of today (2026-06-25), Alkermes's current stock price is $53.14. Alkermes's E10 for the quarter that ended in Mar. 2026 was $-0.19. Alkermes's Shiller PE Ratio of today is .


Alkermes  (NAS:ALKS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Alkermes E10 Related Terms


Alkermes E10 Historical Data

* Premium members only.

The historical data trend for Alkermes's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes E10 Chart

Alkermes Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.80 -0.92 -0.77 -0.53 -0.21

Alkermes Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.50 -0.41 -0.30 -0.21 -0.19

ALKS vs LNTH, HIMS, LQDA: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alkermes's Shiller PE Ratio falls into.


ALKS
70GF Score
Alkermes PLC ALKS
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alkermes E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alkermes's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.4/125.8201*125.8201
=-0.400

Current CPI (Mar. 2026) = 125.8201.

Alkermes Quarterly Data

per share eps CPI Adj_EPS
201606 -0.310 101.072 -0.386
201609 -0.410 100.274 -0.514
201612 -0.140 99.676 -0.177
201703 -0.450 100.374 -0.564
201706 -0.280 100.673 -0.350
201709 -0.240 100.474 -0.301
201712 -0.060 100.075 -0.075
201803 -0.400 100.573 -0.500
201806 -0.210 101.072 -0.261
201809 -0.220 101.371 -0.273
201812 -0.060 100.773 -0.075
201903 -0.620 101.670 -0.767
201906 -0.270 102.168 -0.333
201909 -0.340 102.268 -0.418
201912 -0.030 102.068 -0.037
202003 -0.240 102.367 -0.295
202006 -0.190 101.769 -0.235
202009 -0.001 101.072 -0.001
202012 -0.270 101.072 -0.336
202103 -0.140 102.367 -0.172
202106 0.010 103.364 0.012
202109 -0.180 104.859 -0.216
202112 0.010 106.653 0.012
202203 -0.220 109.245 -0.253
202206 -0.180 112.779 -0.201
202209 -0.390 113.504 -0.432
202212 -0.170 115.436 -0.185
202303 -0.250 117.609 -0.267
202306 1.380 119.662 1.451
202309 0.280 120.749 0.292
202312 0.660 120.749 0.688
202403 0.210 120.990 0.218
202406 0.530 122.318 0.545
202409 0.550 121.594 0.569
202412 0.880 122.439 0.904
202503 0.130 123.405 0.133
202506 0.520 124.492 0.526
202509 0.490 124.854 0.494
202512 0.290 125.820 0.290
202603 -0.400 125.820 -0.400

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-0.19 mean?
Alkermes (ALKS) has a E10 of $-0.19 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Alkermes and its competitors.
Is Alkermes' E10 too high?
Alkermes' current E10 is $-0.19. Overall, Alkermes has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' E10 compare to LNTH and HIMS?
Alkermes' E10 of $-0.19 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Alkermes and its competitors. Alkermes's current E10 is $-0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (ALKS) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.33, compared to a current price of $53.14 — trading 69.6% above its estimated fair value. The current E10 is $-0.19. Alkermes' overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Alkermes (ALKS), the current E10 is $-0.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alkermes (ALKS) Overvalued in 2026?

Based on GuruFocus' analysis, Alkermes stock appears to be overvalued. The current stock price of $53.14 is trading 69.6% above its estimated GF Value™ of $31.33. GuruFocus considers Alkermes to be Significantly Overvalued.

Key valuation signals for ALKS:

  • E10: $-0.19
  • GF Value™: $31.33 vs. price of $53.14 (69.6% above fair value)
  • GF Score™: 70/100 with 8 warning signs

No single metric tells the full story. See the ALKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alkermes Business Description

Other Exchanges 8AK:Germany
Address 1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
70GF Score

Get the complete analysis for ALKS

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.14
Price
$31.33
GF Value